Mitokinin Overview
- Year Founded
-
2017
- Status
-
Acquired/Merged
- Employees
-
11
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$110M
Mitokinin General Information
Description
Developer of a small molecule therapeutics designed to increase the activity of active-form PINK1. The company offers compounds that do not interfere with the endogenous regulation of PINK1 and its team of neuroscientists, chemists, pharmacologists, and administrative professionals is dedicated to delivering disease-modifying therapies in this field, enabling healthcare providers to treat neurodegenerative disease with the advancement of therapies.
Contact Information
Website
www.mitokinin.comCorporate Office
- 953 Indiana Street
- San Francisco, CA 94107
- United States
Corporate Office
- 953 Indiana Street
- San Francisco, CA 94107
- United States
Mitokinin Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 04-Oct-2023 | $110M | Completed | Generating Revenue | ||
| 4. Grant | 25-Oct-2019 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series A1) | 01-Jan-2019 | Completed | Generating Revenue | |||
| 2. Grant | 01-Jan-2018 | $225K | $4.53M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 12-Sep-2017 | $4.53M | $4.53M | Completed | Startup |
Mitokinin Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
Mitokinin Patents
Mitokinin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260356839-A1 | Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof | Pending | 19-Aug-2022 | ||
| WO-2024040267-A2 | Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof | Inactive | 19-Aug-2022 | ||
| WO-2024040267-A3 | Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof | Inactive | 19-Aug-2022 | ||
| WO-2024040266-A2 | Disubstituted benzoimidazole and indole analogs as modulators of pink1 | Inactive | 19-Aug-2022 | ||
| WO-2024040266-A3 | Disubstituted benzoimidazole and indole analogs as modulators of pink1 | Inactive | 19-Aug-2022 | C07D471/04 |
Mitokinin Signals
Mitokinin Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Michael J. Fox Foundation | Limited Partner | |||
| Mission Bay Capital | Venture Capital | Minority | ||
| Mission BioCapital | Venture Capital | Minority | ||
| Novartis Institutes for BioMedical Research | Corporation | Minority | ||
| Pfizer Ventures | Corporate Venture Capital | Minority |
Mitokinin FAQs
-
When was Mitokinin founded?
Mitokinin was founded in 2017.
-
Where is Mitokinin headquartered?
Mitokinin is headquartered in San Francisco, CA.
-
What is the size of Mitokinin?
Mitokinin has 11 total employees.
-
What industry is Mitokinin in?
Mitokinin’s primary industry is Drug Discovery.
-
Is Mitokinin a private or public company?
Mitokinin is a Private company.
-
What is the current valuation of Mitokinin?
The current valuation of Mitokinin is .
-
What is Mitokinin’s current revenue?
The current revenue for Mitokinin is .
-
How much funding has Mitokinin raised over time?
Mitokinin has raised $9.5M.
-
Who are Mitokinin’s investors?
Michael J. Fox Foundation, Mission Bay Capital, Mission BioCapital, Novartis Institutes for BioMedical Research, and Pfizer Ventures are 5 of 9 investors who have invested in Mitokinin.
-
When was Mitokinin acquired?
Mitokinin was acquired on 04-Oct-2023.
-
Who acquired Mitokinin?
Mitokinin was acquired by AbbVie.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process